Twist Bioscience (TWST)
(Delayed Data from NSDQ)
$42.37 USD
-0.83 (-1.92%)
Updated May 10, 2024 04:00 PM ET
After-Market: $42.40 +0.03 (0.07%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth B Momentum C VGM
Balance Sheet
Fiscal Year End for Twist Bioscience Corporation falls in the month of September.
All items in Millions except Per Share data.
9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 336 | 505 | 478 | 290 | 138 |
Receivables | 44 | 40 | 29 | 26 | 12 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 32 | 39 | 32 | 12 | 7 |
Other Current Assets | 12 | 12 | 8 | 6 | 3 |
Total Current Assets | 424 | 596 | 547 | 335 | 160 |
Net Property & Equipment | 132 | 139 | 44 | 25 | 21 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 140 | 146 | 41 | 1 | 2 |
Deposits & Other Assets | 8 | 5 | 9 | 3 | 4 |
Total Assets | 776 | 961 | 702 | 399 | 187 |
Liabilities & Shareholders Equity | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 14 | 20 | 15 | 5 | 10 |
Current Portion Long-Term Debt | 0 | 0 | 2 | 3 | 3 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 37 | 37 | 29 | 19 | 16 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 8 | 20 | 10 | 3 | 1 |
Total Current Liabilities | 73 | 91 | 63 | 36 | 30 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 1 | 4 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 5 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 153 | 172 | 121 | 63 | 35 |
Shareholders Equity | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,657 | 1,620 | 1,191 | 795 | 470 |
Retained Earnings | -1,033 | -828 | -611 | -458 | -319 |
Other Equity | -1 | -2 | 1 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 623 | 789 | 581 | 336 | 152 |
Total Liabilities & Shareholder's Equity | 776 | 961 | 702 | 399 | 187 |
Total Common Equity | 623 | 789 | 581 | 336 | 152 |
Shares Outstanding | 57.40 | 56.30 | 49.20 | 44.60 | 32.80 |
Book Value Per Share | 10.86 | 14.02 | 11.81 | 7.54 | 4.64 |
Fiscal Year End for Twist Bioscience Corporation falls in the month of September.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 293 | 311 | 336 | 357 | 388 |
Receivables | 36 | 35 | 44 | 43 | 48 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 30 | 31 | 32 | 36 | 40 |
Other Current Assets | 12 | 13 | 12 | 9 | 14 |
Total Current Assets | 372 | 390 | 424 | 446 | 489 |
Net Property & Equipment | 121 | 126 | 132 | 141 | 147 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 138 | 139 | 140 | 142 | 143 |
Deposits & Other Assets | 8 | 8 | 8 | 10 | 5 |
Total Assets | 703 | 733 | 776 | 810 | 854 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 8 | 9 | 14 | 12 | 13 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 40 | 35 | 37 | 38 | 35 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 5 | 6 | 8 | 10 | 10 |
Total Current Liabilities | 67 | 65 | 73 | 73 | 72 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 143 | 143 | 153 | 153 | 150 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,682 | 1,667 | 1,657 | 1,645 | 1,633 |
Retained Earnings | -1,122 | -1,076 | -1,033 | -987 | -929 |
Other Equity | -1 | -1 | -1 | -1 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 560 | 590 | 623 | 658 | 704 |
Total Liabilities & Shareholder's Equity | 703 | 733 | 776 | 810 | 854 |
Total Common Equity | 560 | 590 | 623 | 658 | 704 |
Shares Outstanding | 58.20 | 57.80 | 57.40 | 57.10 | 56.80 |
Book Value Per Share | 9.62 | 10.21 | 10.86 | 11.52 | 12.39 |